Physician profile
Maher Salam
NPI 1114002680
$3,784.38
in general payments reported to CMS, 2019-2025
32 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $311 · 2021: $66.79 · 2022: $52.83 · 2023: $399 · 2024: $708 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.29 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.93 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.27 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $302.37 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $202.44 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $201.06 | 2019-2025 | |
| Pfizer INC. | $165.44 | 2019-2020 | |
| Shionogi INC | $150.37 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $145.35 | 2019-2025 | Rebyota |
| Genzyme Corporation | $141.47 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $138.64 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $110.68 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $79.52 | 2019-2020 | |
| Celgene Corporation | $70.94 | 2022-2023 | Zeposia |
| Shire North American Group INC | $53.15 | 2019 | |
| Braintree Laboratories, INC. | $51.80 | 2019-2024 | Suflave, Sutab |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.85 | 2024 | Omvoh |
| Boston Scientific Corporation | $40.12 | 2025 | Resolution 360 Ultra Clip |
| Mallinckrodt Hospital Products INC. | $32.19 | 2024 | Terlivaz |
| Evoke Pharma, INC. | $28.93 | 2020-2025 | |
| Alfasigma USA, INC. | $26.95 | 2020 | |
| Novo Nordisk INC | $22.91 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $21.68 | 2024 | Iqirvo |
| Organon LLC | $20.53 | 2023 | Hadlima, Renflexis |
| Daiichi Sankyo INC. | $19.66 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.89 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $16.50 | 2019 | |
| Cook Medical LLC | $16.45 | 2024 | Hemospray, Fusion |
| Madrigal Pharmaceuticals | $15.20 | 2025 | Rezdiffra |
| Concordia Pharmaceuticals INC. | $13.54 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.46 | 2021 | |
| Merck Sharp & Dohme LLC | $13.06 | 2023 | Dificid |
| Allergan, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Salam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.